- Research works
- 2 fractional, all time
- Citations
- 0 0.0 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 52% world 28%
Not ranked overall: Anocca (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Anocca (Sweden) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Immunotherapy and Immune Responses, Biosimilars and Bioanalytical Methods and Peptidase Inhibition and Analysis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 0 works
- 2 Immunotherapy and Immune Responses Immunology 0 works
- 3 Biosimilars and Bioanalytical Methods Immunology 0 works
- 4 Peptidase Inhibition and Analysis Oncology 0 works
- 5 HER2/EGFR in Cancer Research Oncology 0 works
- 6 Colorectal Cancer Treatments and Studies Oncology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
Other research institutions in Södertälje
- AstraZeneca (Sweden)
- Scania (Sweden)
- Södertälje Sjukhus
- Nanologica (Sweden)
- Noviga Research (Sweden)
- Nordic BioAnalyis (Sweden)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.